New cholesterol-lowering medications
Pro Research Analysisby 
Searched over 200M research papers
New Cholesterol-Lowering Medications: Key Drug Classes and Mechanisms
Statins and Ezetimibe: Established Therapies
Statins remain the primary treatment for lowering LDL cholesterol and preventing cardiovascular disease, but some patients do not reach their cholesterol goals or cannot tolerate statins due to side effects. Ezetimibe, which blocks cholesterol absorption in the intestines, is another established option and can be used alone or in combination with statins for additional LDL reduction 478.
PCSK9 Inhibitors: Monoclonal Antibodies and siRNA
A major advance in recent years is the development of PCSK9 inhibitors. These drugs, including monoclonal antibodies like evolocumab and alirocumab, significantly lower LDL cholesterol by preventing the breakdown of LDL receptors in the liver, leading to increased clearance of LDL from the blood. Clinical trials have shown that PCSK9 inhibitors can reduce LDL cholesterol by over 50% and lower cardiovascular risk, especially in patients who do not respond adequately to statins 1247+1 MORE.
Inclisiran, a small interfering RNA (siRNA) therapy, is a newer PCSK9 inhibitor that works by blocking the production of PCSK9 at the genetic level. Inclisiran is notable for its twice-yearly dosing, which may improve patient adherence, and has shown a similar LDL-lowering effect of about 50% with good safety and tolerability 2469+1 MORE.
Bempedoic Acid: Oral ATP Citrate Lyase Inhibitor
Bempedoic acid is a recently approved oral medication that inhibits ATP citrate lyase, an enzyme involved in cholesterol synthesis. It lowers LDL cholesterol and has demonstrated a reduction in major cardiovascular events in both primary and secondary prevention settings. Bempedoic acid is especially useful for patients who cannot tolerate statins 247.
Other Novel and Emerging Agents
Several other new drugs are being developed or have recently become available:
- ANGPTL3 Inhibitors: These target angiopoietin-like protein 3 and can lower both LDL cholesterol and triglycerides 23.
- Mipomersen and Lomitapide: These drugs are used mainly for patients with familial hypercholesterolemia and work through mechanisms independent of the LDL receptor 13.
- Gemcabene and ETC-1002: These agents lower LDL cholesterol through different pathways and are being explored for patients who do not respond to conventional therapies 13.
- Oligonucleotide Therapeutics: Small interfering RNA (siRNA) and antisense oligonucleotides represent a new class of drugs that target cholesterol metabolism at the RNA level, offering new possibilities for treatment 1310.
Berberine: A Unique Mechanism
Berberine, a compound derived from Chinese herbs, has shown cholesterol-lowering effects through a mechanism distinct from statins. It increases LDL receptor expression in the liver by stabilizing LDL receptor mRNA, leading to significant reductions in LDL cholesterol and triglycerides .
Conclusion
While statins remain the foundation of cholesterol-lowering therapy, new medications such as PCSK9 inhibitors (including monoclonal antibodies and siRNA therapies like inclisiran), bempedoic acid, ANGPTL3 inhibitors, and other novel agents are expanding the options for patients who cannot achieve their cholesterol goals with traditional treatments. These new drugs offer diverse mechanisms of action, improved efficacy, and better tolerability, marking significant progress in the management of high cholesterol and cardiovascular risk 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic